Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992 Moscow, Russia.
SREC PFUR, Peoples' Friendship University of Russia (RUDN University), 117198 Moscow, Russia.
Int J Mol Sci. 2020 Dec 16;21(24):9577. doi: 10.3390/ijms21249577.
Neuroinflammation is a key process of many neurodegenerative diseases and other brain disturbances, and astrocytes play an essential role in neuroinflammation. Therefore, the regulation of astrocyte responses for inflammatory stimuli, using small molecules, is a potential therapeutic strategy. We investigated the potency of peroxisome proliferator-activated receptor (PPAR) ligands to modulate the stimulating effect of lipopolysaccharide (LPS) in the primary rat astrocytes on (1) polyunsaturated fatty acid (PUFAs) derivative (oxylipins) synthesis; (2) cytokines TNFα and interleukin-10 (IL-10) release; (3) p38, JNK, ERK mitogen-activated protein kinase (MAPKs) phosphorylation. Astrocytes were exposed to LPS alone or in combination with the PPAR ligands: PPARα (fenofibrate, GW6471); PPARβ (GW501516, GSK0660); PPARγ (rosiglitazone, GW9662). We detected 28 oxylipins with mass spectrometry (UPLC-MS/MS), classified according to their metabolic pathways: cyclooxygenase (COX), cytochrome P450 monooxygenases (CYP), lipoxygenase (LOX) and PUFAs: arachidonic (AA), docosahexaenoic (DHA), eicosapentaenoic (EPA). All tested PPAR ligands decrease COX-derived oxylipins; both PPARβ ligands possessed the strongest effect. The PPARβ agonist, GW501516 is a strong inducer of pro-resolution substances, derivatives of DHA: 4-HDoHE, 11-HDoHE, 17-HDoHE. All tested PPAR ligands decreased the release of the proinflammatory cytokine, TNFα. The PPARβ agonist GW501516 and the PPARγ agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFα) was more for GW501516. The PPARβ ligands, GW501516 and GSK0660, are also the strongest inhibitors of LPS-induced phosphorylation of p38, JNK, ERK MAPKs. Overall, our data revealed that the PPARβ ligands are a potential pro-resolution and anti-inflammatory drug for targeting glia-mediated neuroinflammation.
神经炎症是许多神经退行性疾病和其他脑紊乱的关键过程,星形胶质细胞在神经炎症中起着至关重要的作用。因此,使用小分子调节星形胶质细胞对炎症刺激的反应是一种潜在的治疗策略。我们研究了过氧化物酶体增殖物激活受体 (PPAR) 配体的效力,以调节脂多糖 (LPS) 在原代大鼠星形胶质细胞中的刺激作用,包括:(1)多不饱和脂肪酸 (PUFA) 衍生物(氧化脂质)的合成;(2)细胞因子 TNFα 和白细胞介素-10 (IL-10) 的释放;(3)p38、JNK、ERK 丝裂原激活蛋白激酶 (MAPKs) 磷酸化。星形胶质细胞单独或与 PPAR 配体(PPARα:非诺贝特、GW6471;PPARβ:GW501516、GSK0660;PPARγ:罗格列酮、GW9662)一起暴露于 LPS 中。我们使用液质联用(UPLC-MS/MS)检测了 28 种氧化脂质,并根据其代谢途径进行了分类:环氧化酶 (COX)、细胞色素 P450 单加氧酶 (CYP)、脂氧合酶 (LOX) 和多不饱和脂肪酸 (PUFA):花生四烯酸 (AA)、二十二碳六烯酸 (DHA)、二十碳五烯酸 (EPA)。所有测试的 PPAR 配体均降低 COX 衍生的氧化脂质;两种 PPARβ 配体的作用最强。PPARβ 激动剂 GW501516 是一种强烈的促解决物质诱导剂,是 DHA 的衍生物:4-HDoHE、11-HDoHE、17-HDoHE。所有测试的 PPAR 配体均降低了促炎细胞因子 TNFα 的释放。PPARβ 激动剂 GW501516 和 PPARγ 激动剂罗格列酮诱导抗炎细胞因子 IL-10 的释放;细胞因子指数(IL-10/TNFα)对于 GW501516 更高。PPARβ 配体 GW501516 和 GSK0660 也是 LPS 诱导的 p38、JNK、ERK MAPKs 磷酸化的最强抑制剂。总的来说,我们的数据表明,PPARβ 配体是一种有潜力的促解决和抗炎药物,可用于靶向神经胶质细胞介导的神经炎症。